Propanc Health Group Corp (OTCMKTS:PPCH) Stabilizes

[[tagnumber 0]][[tagnumber 1]]The overall performance of Propanc Health Group Corp (OTCMKTS:PPCH) since the beginning of the year has been pretty decent. We have seen the stock gain some value, despite the red sessions and the daily volumes have significantly increased.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]May was somewhat quieter than the previous months and we saw [[tagnumber 6]]PPCH[[tagnumber 7]] hover around the 5 cent mark on relatively low volumes most of the time. On May 27, however, the ticker was touted by SeeThruEquity who gave it a price target of $1.52.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]This led to an impressive 88.76% gain during the session and the massive 71.2 million shares that changed their owners while the ticker was going for a close at $0.084 generated a total of $5.15 million in daily dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The hype quickly turned cold and we saw [[tagnumber 6]]PPCH[[tagnumber 7]] close the next two sessions in the red. It couldn’t be any other way. After all, the market cap that had reached nearly $25 million was a little inflated when you compare it to the book value of the company which we discussed in our previous article.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Furthermore, [[tagnumber 6]]PPHC [[tagnumber 7]]is far from producing a revenue–generating product. They have only one drug that is in the process of obtaining an FDA approval and it is still currently undergoing animal trials.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Still, the ticker did manage to start the week positively, gaining 14.21% in yesterday’s session and closing at $0.0651. Only time will tell if it can push further up, but you should be sure to do your due diligence and weigh out the risks before making any investment decisions.[[tagnumber 2]]